Benzhydrocodone

Products

Benzhydrocodone was approved in the United States in 2018 as a fixed combination with acetaminophen in tablet form with a modified release of active ingredient (Apadaz).

Structure and properties

Benzhydrocodone (C₂₅H₂₅NO₄, M_r = 403.5 g/mol) is an inactive prodrug of hydrocodone. It is an ester of benzoic acid with the opioid that is enzymatically metabolized in the intestine to the active drug. Use of the prodrug reduces the potential for abuse due to altered pharmacokinetics. Benzhydrocodone is present in the drug as benzhydrocodone hydrochloride.

Effects

Hydrocodone (ATC R05DA03) has analgesic properties. The effects are due to binding the μ-opioid receptors.

Indications

For short-term treatment of pain (maximum 14 days).